Free Trial
OTCMKTS:CLPBY

Coloplast A/S 5/6/2025 Earnings Report

Coloplast A/S logo
$6.33 +0.03 (+0.48%)
As of 05/11/2026 03:59 PM Eastern

Coloplast A/S EPS Results

Actual EPS
$0.06
Consensus EPS
$0.09
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Coloplast A/S Revenue Results

Actual Revenue
$1.05 billion
Expected Revenue
$7.02 billion
Beat/Miss
Missed by -$5.97 billion
YoY Revenue Growth
N/A

Coloplast A/S Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Coloplast A/S' next earnings date is estimated for Tuesday, May 12, 2026, based on past reporting schedules.

Conference Call Resources

Coloplast A/S Earnings Headlines

Coloplast appoints Gavin Wood as new CEO
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2025 - says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. When the Fed cut rates in 2020, his readers had a chance at 62% gains. A 2022 rate-hike signal produced 117% in under a month. Now Benedict has identified the single ticker he believes will be at the center of the coming money flows - and he's revealing it free before May 15.tc pixel
Coloplast A/S - Updated Financial Calendar 2025-26
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste. The continence care segment offers catheters, drainage bags and related supplies for individuals with bladder control issues. The company’s wound and skin care portfolio includes advanced dressings, negative-pressure wound therapy and pressure ulcer prevention products, while its interventional urology line features devices for minimally invasive procedures and diagnostics in urological conditions.

Founded in 1957 by Danish entrepreneur Aage Louis-Hansen, Coloplast began when Louis-Hansen developed the first adhesive ostomy bag to help his wife manage her postoperative care. Since then, the company has grown from a small family operation into a publicly listed corporation on the Copenhagen Stock Exchange, with an American depositary receipt program trading under the symbol CLPBY in the U.S. The company is led by President and CEO Peter Clemmensen, who has overseen continued expansion of R&D and manufacturing capabilities.

Headquartered in Humlebæk, Denmark, Coloplast operates manufacturing and research facilities across Europe and North America, supported by a global sales and distribution network. Its products are available in more than 100 countries, with regional offices and partnerships that ensure local market support and training for healthcare professionals. The company places a strong emphasis on customer proximity and collaborative development to address the evolving needs of patients and clinicians worldwide.

View Coloplast A/S Profile